Horizon Discovery chairman steps down from Board
pharmafile | October 24, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | evans, horizon
Research tools firm Horizon Discovery has confirmed that David Evans has stepped down as chairman of its Board.
Dr Ian Gilham, who was recently appointed as a non-executive director for the company, will act as its interim chairman. Horizon is currently seeking a non-executive with international standing to act as chairman, who will work closely with the Board of directors and chief executive.
Evans has been non-executive chairman at Horizon since 2009. During this time he oversaw the company’s growth and as an entrepreneurial accountant was involved in various organisations in the diagnostics and life sciences fields.
Dr Darrin Disley, chief executive of Horizon, said: “On behalf of Horizon’s management team and Board of directors I would like to thank David for his integrity, hard work and unwavering support. He remains a significant investor, trusted advisor and friend of the company and we wish him well.
“As interim chairman Ian’s commercial and investor relations experience will be greatly valued, as Horizon continues to develop as a world-leading translational genomics organization.”
Evans added: “It has been a pleasure to work with Horizon, one of the leading lights of the British biotech industry. The company has a strong future ahead, and I look forward to seeing its growth over the coming years.”
Gilham was appointed non-executive director for the firm in August 2013. He is also non-executive chairman of Multiplicom NV and Biosurfit SA, and director of Stowheath Ltd. He has previously been chief executive of Axis-Shield and VP, Pharmacogenetics and Diagnostics at GSK, as well as holding various positions within Abbott.
Related Content
Horizon and Fulcrum Therapeutics form CRISPR collaboration
Horizon Discovery has announced that it has entered into a partnership with Fulcrum Therapeutics to …
Horizon to acquire worldwide rights to Boehringer Ingelheim genetic disease drug
Horizon Pharmaceuticals (NASDAQ: HZNP) has entered into a worldwide rights agreement with Boehringer Ingelheim to …
Depomed criticised by investors and urged to explore potential sale
Only a few short months after fighting off a $1 billion bid from Horizon Pharma, …